Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer
Phase III Randomized Evaluation of Adjuvant Radiotherapy vs No Adjuvant Therapy Following Radical Prostatectomy and Pelvic Lymphadenectomy in Surgical Stage C Adenocarcinoma of the Prostate
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
I. Compare disease-free survival rates of patients randomly assigned to adjuvant external-beam radiotherapy vs. no adjuvant therapy following radical prostatectomy and pelvic lymphadenectomy for surgical Stage C (T3 N0 M0) adenocarcinoma of the prostate.
II. Determine the qualitative and quantitative toxicities associated with this adjuvant therapy.
OUTLINE: Randomized study. Randomization takes place when the patient is physically able to begin treatment, any time within 16 weeks after surgery.
Arm I: Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
Arm II: No further treatment.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Pathologically documented Stage C (T3 N0 M0) adenocarcinoma of the prostate following radical prostatectomy and pelvic lymphadenectomy for clinical Stage A/B disease
- Ineligible for SWOG protocols of higher priority
At least 1 of the following on pathologic examination:
- Presence of cancer in the seminal vesicles
- Evidence of cancer at the inked surgical margin of the prostate
- Extension of tumor beyond the prostatic capsule
Negative preoperative metastatic survey within 6 months prior to registration, including the following:
- Normal bone scan
- No palpable evidence of extraprostatic tumor extension
- Bilateral lymph node dissection histologically negative for cancer
Nodal sampling not required with the following stage/biopsy specimen Gleason score/preoperative PSA:
- Stage T1a/2-6/<10 ng/ml
- Stage T1b-c/2-5/<10 ng/ml
- Stage T2a/2-6/<10 ng/ml
- Stage T2b/2-6/<6 ng/ml
- Stage T2c/2-6/<4 ng/ml
Free from the following postoperative complications:
- Total urinary incontinence
- Intraoperative rectal injury
- persistent urinary extravasation
- Pelvic infection
- Concurrent registration on protocol SWOG-9205 (serum repository protocol) optional
- Concurrent registration on protocol SWOG-8994 (quality-of-life study) required of English-speaking and Spanish-speaking patients enrolled by SWOG
--Patient Characteristics--
- Age: Any age
- Performance status: SWOG 0-2
- Life expectancy: At least 2 years
Hematopoietic:
- WBC at least institutional LLN
- Platelets at least institutional LLN
- Hepatic: SGOT no more than 2 x ULN
- Other: No second malignancy within 5 years except adequately treated nonmelanomatous skin cancer
--Prior Concurrent Therapy--
- Chemotherapy: No prior chemotherapy for prostate cancer
- Endocrine therapy: No more than 3 months of hormonal therapy prior to prostatectomy allowed
- Radiotherapy: No prior radiotherapy for prostate cancer
- Surgery: Radical prostatectomy and pelvic lymphadenectomy within 16 weeks prior to registration required
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm I
Radiotherapy.
Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
|
|
|
Ingen indgriben: Arm II
No further treatment.
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Generelle publikationer
- Thompson IM, Paradelo JC, Crawford ED, Coltman CA, Blumenstein B. An opportunity to determine optimal treatment of pT3 prostate cancer: the window may be closing. Urology. 1994 Dec;44(6):804-11. doi: 10.1016/s0090-4295(94)80161-4. No abstract available.
- Swanson GP, Thompson IM, Tangem C, et al.: Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794). [Abstract] Int J Radiat Oncol Biol Phys 63 (Suppl 1): A-1, S1, 2005.
- Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15;296(19):2329-35. doi: 10.1001/jama.296.19.2329.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NCI-2012-02483
- SWOG-8794
- CAN-NCIC-PR2
- CLB-9493
- EST-9887
- NCCTG-895251
- RTOG-9019
- INT-0086
- CDR0000075112 (Registry Identifier: PDQ (Physician Data Query))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .